PREPARATION OF MULTICOMPONENT CRYSTAL TICAGRELOR-MEGLUMINE AND ITS PHYSICOCHEMICAL CHARACTERIZATION
DOI:
https://doi.org/10.22159/ijap.2025v17i3.53485Keywords:
Ticagrelor, Meglumine, Multicomponent crystal, Eutectic mixture, Dissolution rate, SolubilityAbstract
Objective: Ticagrelor (TICA), an antiplatelet agent used in cardiovascular treatment, is classified as a Class IV compound in the Biopharmaceutical Classification System, characterized by low solubility and low permeability, leading to poor bioavailability. This study aimed to enhance the solubility and dissolution rate of TICA through the formation of a multicomponent crystal with meglumine.
Methods: Multicomponent crystals were prepared using the solvent drop grinding method. A binary phase diagram of ticagrelor and Meglumine (MEG) was constructed to determine the eutectic composition and temperature. Characterization was conducted using Differential Scanning Calorimetry, Fourier Transform Infrared Spectroscopy, Powder X-ray diffraction, and Scanning Electron Microscopy. Solubility tests and in vitro dissolution studies were performed to evaluate improvements in solubility and dissolution rate.
Results: The binary phase diagram confirmed a simple eutectic mixture at a 4:6 molar ratio, with a eutectic temperature of 124.31 °C. The multicomponent crystal demonstrated 1.4 times higher solubility compared to intact ticagrelor. Dissolution studies showed significant improvements: 70.44% in 0.1 N HCl and 62.27% in CO₂-free distilled water within 60 min, compared to 40.39% and 31.38%, respectively, for intact TICA (P<0.05).
Conclusion: The formation of TICA and MEG multicomponent crystals significantly enhanced solubility and dissolution rates, suggesting its potential to improve the bioavailability of TICA. This approach highlights the promise of multicomponent crystal technology in addressing the bioavailability challenges of Class IV drugs.
References
Zaini E, Azhari D, Fitriani L. Identification and characterization of solid binary system of quercetin nicotinamide. Orient J Chem. 2016;32(3):1545-50. doi: 10.13005/ojc/320330.
Putra OD, Furuishi T, Yonemochi E, Terada K, Uekusa H. Drug-drug multicomponent crystals as an effective technique to overcome weaknesses in parent drugs. Cryst Growth Des. 2016;16(7):3577-81. doi: 10.1021/acs.cgd.6b00639.
Grothe E, Meekes H, Vlieg E, Ter Horst JH, DE Gelder R. Solvates salts and cocrystals: a proposal for a feasible classification system. Cryst Growth Des. 2016;16(6):3237-43. doi: 10.1021/acs.cgd.6b00200.
Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: a review of preparations physicochemical properties and applications. Acta Pharm Sin B. 2021;11(8):2537-64. doi: 10.1016/j.apsb.2021.03.030, PMID 34522597.
Bayoumi AA. Enhancement of solubility of a poorly soluble antiplatelet aggregation drug by cogrinding technique. Asian J Pharm Clin Res. 2018;11(10). doi: 10.22159/ajpcr.2018.v11i10.27136.
Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics pharmacodynamics clinical efficacy and safety. Pharmacotherapy. 2014;34(10):1077-90. doi: 10.1002/phar.1477, PMID 25164528.
Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J. 2011;32(23):2999-3054. doi: 10.1093/eurheartj/ehr236, PMID 21873419.
Chaudhari S, Dhumal SV, Daswadkar, Shirode D. Study of formulation variables on bioavailability of metformin hydrochloride. Medicine Chemistry 2016;3(11):484-97.
Ashok KA, Wahid AA. Formulation development and absorption enhancement of metformin hydrochloride by using spray drying technique. SJIF J. 2021;2(5):1685-703. doi: 10.20959/wjpr202317-29690.
Manconi M, Nacher A, Merino V, Merino Sanjuan M, Manca ML, Mura C. Improving oral bioavailability and pharmacokinetics of liposomal metformin by glycerolphosphate chitosan microcomplexation. AAPS Pharm Sci Tech. 2013;14(2):485-96. doi: 10.1208/s12249-013-9926-4, PMID 23471836.
Kumar A, Bansal M. Formulation and evaluation of antidiabetic tablets: effect of absorption enhancer. SJIF J. 2021;2(5):1685-703. doi: 10.20959/wjpr202317-29690.
Adimulapu AK, Srinivasa Rao NS, Anusha A, Banusha S, Akhila V. Formulation development and oral permeability of metformin HCl under the influence of permeability enhancers. Res J Pharm Technol. 2024;17(7):3209-12. doi: 10.52711/0974-360X.2024.00502.
Docherty R, Pencheva K, Abramov YA. Low solubility in drug development: de-convoluting the relative importance of solvation and crystal packing. J Pharm Pharmacol. 2015;67(6):847-56. doi: 10.1111/jphp.12393, PMID 25880016.
Haneef J, Arora P, Chadha R. Implication of coformer structural diversity on cocrystallization outcomes of telmisartan with improved biopharmaceutical performance. AAPS Pharm Sci Tech. 2019;21(1):10. doi: 10.1208/s12249-019-1559-9, PMID 31802267.
Shane NL, Chamle AH, Vasantharaju V, Pai A, Pai G, Sathyanarayana MB. Fabrication and solid state characterization of ticagrelor co-crystals with improved solubility and dissolution. Int J Pharm Qual Assur. 2017;8(1):1-8. doi: 10.25258/ijpqa.v8i1.8433.
Shane, Pai, Pai, Pai V SG, Sathyanarayana. Solubility enhancement of ticagrelor by co-crystal technology: preparation solid-state characterization and solubility studies. Lat Am J Pharm. 2019;38(10):2051-6.
Inam M, WU J, Shen J, Phan CU, Tang G, HU X. Preparation and characterization of novel pharmaceutical co-crystals: ticagrelor with nicotinamide. Crystals. 2018;8(9):336. doi: 10.3390/cryst8090336.
Erizal SY, Cahyati SY, Nurono SS, Halim A. Effect of milling on solid-state transformation of sulfamethoxazole. Int J Pharmacol. 2008;4(2):140-4. doi: 10.3923/ijp.2008.140.144.
Fitriani L, Fadina H, Usman H, Zaini E. Formation and characterization of multicomponent crystal of trimethoprim and mandelic acid by solvent drop grinding method. Int J App Pharm. 2023;15(1):75-9. doi: 10.22159/ijap.2023.v15s1.06.
Zaini E, Fitriani L, Effendy S, Noviza D, Halim A. Preparation and characterization of solid dispersion telmisartan hydroxypropyl methylcellulose (HPMC) e5 lv by co-grinding method. Orient J Chem. 2017;33(2):873-8. doi: 10.13005/ojc/330236.
Fandaruff C, Quiros Fallas MI, Vega Baudrit JR, Navarro Hoyos M, Lamas DG, Araya Sibaja AM. Saquinavir piperine eutectic mixture: preparation characterization and dissolution profile. Pharmaceutics. 2023;15(10):2446. doi: 10.3390/pharmaceutics15102446, PMID 37896206.
Hasanah U, Azfitri Y, Fitriani L, Zaini E. Tenoxicam tromethamine multicomponent crystal: physicochemical characteristics solubility and dissolution evaluation. Int J App Pharm. 2024;16(1):23-7. doi: 10.22159/ijap.2024.v16s1.04.
Martin AN, Sinko PJ, Singh Y. Martins physical pharmacy and pharmaceutical sciences. 6th editio. Philadelphia: Lippincott Williams & Wilkins; 2011.
Gorniak A, Wojakowska A, Karolewicz B, Pluta J. Phase diagram and dissolution studies of the fenofibrate acetylsalicylic acid system. J Therm Anal Calorim. 2011;104(3):1195-200. doi: 10.1007/s10973-010-1148-3.
Umar S, Putri N, Deni B, Erizal A. Multicomponent crystal of fenofibric acid-saccharin: characterization and antihyperlipidemic effectiveness. Adv Heal Sci Res. doi: 10.2991/ahsr.k.211105.015.
Dwichandra Putra O, Yonemochi E, Uekusa H. Isostructural multicomponent gliclazide crystals with improved solubility. Cryst Growth Des. 2016;16(11):6568-73. doi: 10.1021/acs.cgd.6b01279.
Ainurofiq A, Mauludin R, Mudhakir D, Setianto AB, Soewandhi SN. The effect of compression force on alteration of desloratadine and its multicomponent crystal crystallinities using x-ray diffraction and atr-ftir techniques. Key Eng Mater. 2018;787:43-51. doi: 10.4028/www.scientific.net/KEM.787.43.
Sarma JA, Desiraju GR. The supramolecular synthon approach to crystal structure prediction. Cryst Growth Des. 2002;2(2):93-100. doi: 10.1021/cg015576u.
Bazzo GC, Pezzini BR, Stulzer HK. Eutectic mixtures as an approach to enhance solubility dissolution rate and oral bioavailability of poorly water-soluble drugs. Int J Pharm. 2020 Aug;588:119741. doi: 10.1016/j.ijpharm.2020.119741, PMID 32783978.
Munteanu C, Teoibas Serban D, Iordache L, Balaurea M, Blendea CD. Water intake meets the water from inside the human body physiological, cultural and health perspectives synthetic and systematic literature review. Balneo and PRM Research Journal. 2021;12(3):196-209. doi: 10.12680/balneo.2021.439.
Douroumis D, Fahr A. Drug delivery strategies for poorly water-soluble drugs. Drug Deliv. 2013:403-16. doi: 10.1002/9781118444726.
Fitriani L, Rismawati E, Umar S, Zaini E. Solid dispersion of usnic acid-PVP K30 and evaluation of antioxidant activity. Rasayan J Chem. 2018;11(4):1643-8. doi: 10.31788/RJC.2018.1144076.
Petersen EF, Larsen BS, Nielsen RB, Pijpers I, Versweyveld D, Holm R. Co-release of paclitaxel and encequidar from amorphous solid dispersions increase oral paclitaxel bioavailability in rats. Int J Pharm. 2024;654:123965. doi: 10.1016/j.ijpharm.2024.123965, PMID 38442796.
Saikia B, Seidel Morgenstern A, Lorenz H. Multicomponent materials to improve solubility: eutectics of drug aminoglutethimide. Crystals. 2021;12(1):40. doi: 10.3390/cryst12010040.
Higuchi T. Mechanism of sustained action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52(12):1145-9. doi: 10.1002/jps.2600521210, PMID 14088963.
Lapidus H, Lordi NG. Drug release from compressed hydrophilic matrices. J Pharm Sci. 1968;57(8):1292-301. doi: 10.1002/jps.2600570803, PMID 5677330.
Samaha D, Shehayeb R, Kyriacos S. Modeling and comparison of dissolution profiles of diltiazem modified release formulations. Dissolution Technol. 2009;16(2):41-6. doi: 10.14227/DT160209P41.
Published
How to Cite
Issue
Section
Copyright (c) 2025 SALMAN UMAR, AHDI DINIL HAQ AH, MUHAMMAD NASRUL SIREGAR, ERIZAL ZAINI
This work is licensed under a Creative Commons Attribution 4.0 International License.
